依托泊苷（Etoposide）是目前臨床使用的抗癌藥物，主要作用機制為抑制DNA拓樸異構酶II。雖然依托泊苷是世界衛生組織所列的基本藥物，但其製造需要從植物鬼臼中分離出（−）-鬼臼毒素（(−)-podophyllotoxin），再利用人工合成得到。在2015年Sattely團隊研究顯示，此合成中的起始物（−）-鬼臼毒素，是以松柏醇經由多個酵素（DIR、PLR、SDH、 P450、OMT1及2-ODD）催化反應步驟得到。其中，我們有興趣的是Yatein在酵素2-ODD催化下，進行分子內合環反應，得到7-脫氧鬼臼毒素（7-deoxypodophyllotoxin）。為了探討酵素的反應機制，以β-piperonyl-γ-butyrolactone作為共同前驅物，合成酵素的受質Yatein和推測產物7-脫氧鬼臼毒素及其衍生物。我們的結果表明，最初提出的羥基化中間體不太可能參與該反應。相反，苯甲基自由基及碳陽離子中間體的形成可用於觸發碳–碳鍵形成以構建（-）-鬼臼毒素的碳環。

Etoposide is a clinically used anticancer drug. Its mechanism of action is inhibition of DNA topoisomerase II. Although etoposide is a basic drug listed by the World Health Organization, its manufacture requires the isolation of (−)-podophyllotoxin from plant scorpion as the precursor, followed by multi-step chemical synthesis. In 2015, Sattely’s team showed that the biosynthesis of (−)-podophyllotoxin was accomplished from coniferyl alcohol via multiple enzyme catalysis (DIR, PLR, SDH, P450, OMT1 and 2-ODD). In the biosynthetic pathway of (–)-podophyllotoxin, we have been interested to establish a reasonable reaction mechanism for 7-deoxypodophyllotoxin from yatein under 2-ODD-catalyzed oxidative cyclization. To study the 2-ODD catalyzed reaction, the synthesis of mechanistic probes, including yatein and deoxypodophyllotoxin analogs, started with β-piperonyl-γ- butyrolactone as a common precursor was investigated.

1. Jemal, A.; Bray, F.; Center, M.-M.; Ferlay, J.; Ward, E.; Forman, D. CA CANCER J CLIN. 2011, 61, 69–90
2. Wang, J.-C. J. Mol. Biol. 1971, 55, 523–533
3. Depew, R.-E.; Liu, L.-F.; Wang, J.-C. J. Biol. Chem. 1978, 25, 511–518
4. Gellert, M.; Mizuuchi, K.; O'Dea, M.-H.; Nash, H.-A. Proc. Nati. Acad. Sci. USA 1976, 73, 3872–3876
5. Hande, K.-R. Eur. J. Cancer 1998, 34, 1514–1521
6. Jain, S.-M.; Saxena, P.-K. Protocols for in vitro cultures and secondary metabolite analysis of aromatic and medicinal plants. 2009, 387–402
7. Saito, H.; Nishimura, Y.; Kondo, S.; Umezawa, H. Chem. Lett., 1987, 16, 799-802
8. Slevin M.-L. Cancer 1991, 67, 319–329
9. Bedows, E.; Hatfield, G.-M. J. Nat. Prod. 1982, 45, 725–729
10. Greenspan, E.-M.; Lester, J.; Shear, M.-J. J. Natl. Cancer Inst. 1950, 10, 1273–1293
11. Leiter, J.; Downing V.; Hartwell, J. J. Natl. Cancer Inst. 1950, 10, 1273–1293
12. Lau, W.; Sattely, E.-S. Science. 2015, 349, 1224–1228
13. Gao, S.-S.; Naowarojna, N.; Cheng, R.; Liu, X.; Liu, P. Nat. Prod. Rep. 2018, 35, 792–837
14. Islam, M.-S.; Leissing, T.-M.; Chowdhury, R.; Hopkinson, R.-J.; Schofield, C.-J. Annu. Rev. Biochem. 2018, 87, 585–620
15. Martinez, S.; Hausinger, R.-P. J. Biol. Chem. 2015, 290, 20702–20711
16. Groves, J.-T. J. Chem. Educ. 1985, 62, 928-931
17. Chang, W.-C.; Yang, Z.-J.; Tu, Y.-H.; Chien, T.-C. Org. Lett. 2019, 21, 228–232
18. Li, J.; Zhang, X.; Renata, H.
19. Lazzarotto, M.; Hammerer, L.; Hetmann M.; Borg, A.; Schmermund L.; Steiner, L.; Hartmann, P.; Belaj, F.; Kroutil, W.; Gruber, K.; Fuchs, M. Angew. Chem. Int. Ed. 2019, 58, 8226–8230
20. Kuo, Y.-C.; Kuo Y.-H.; Lin, Y.-L.; Tsai, W.-J. Antiviral Res. 2006, 70, 112–120
21. Carnbie, R.-C.; Craw, P.-A.; Rutledge, P.-S.; Woodgate, P.-D. Aust. J. Chem. 1988, 41, 897–918.
22. Duan, S.; Huang, S.; Gong, J.; Shen, Y.; Zeng, L.; Feng, Y.; Ren, W.; Leng, Y.; Hu, Y. ACS Med. Chem. Lett. 2015, 6, 386−391.
23. Chern, J.; Lu C.-P.; Fang Z.; Chang, C.-M.; Hua, K.-F.; Chen, Y.-T.; Ng, C.-Y.; Chen, Y.-S.; Lam Y.; Wu S.-H. Angew. Chem. Int. Ed. 2018, 57, 7040–7045.
24. Davidson, S.-J.; Pearce, A.-N.; Copp, B.-R.; Barker, D. Org. Lett. 2017, 19, 5368–5371.
25. Alizadeh, B.-H.; Foroumadi, A.; Emami, S.; Khoobi, M.; Panah, F.; Ardestani, S.-K.; Shafiee, A. Eur. J. Med. Chem. 2010, 45, 5979−5984.
26. Shekhar, K.-C.; Basnet, P.; Thapa S.; Shrestha B.; Giri R. J. Org. Chem. 2018, 83, 2920–2936
27. Hartmann, P.; Lazzarotto, M.; Steiner, L.; Cigan, E.; Poschenrieder S.; Sagmeister P.; Fuchs, M. J. Org. Chem. 2019, 84, 5831–5837